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2A (Now) Well Known Story
? Hyperglycaemia is prevalent in critical care
? Impaired insulin production + Increased insulin resistance = High BG
? Average blood glucose values > 180mg/dL are not uncommon
? All due to the stress of the patient’s condition
? Tight control ? better outcomes:
? Reduced mortality ~17-43% (6.1-7.75 mmol/L) [van den Berghe, Krinsley]
? Costly treatments & tests (mech. ventilation, transfusions, … ) are also reduced
? $2000/day saved regardless of mortality outcome [van den Berghe, Krinsley]
? However, how best to attack the problem?
? How to manage highly insulin resistant patients (usually high APACHE score)?
? How to provide better safety from hypoglycaemia?
? Initial results have been very hard to repeat to outcome
? Model-based methods may offer an opportunity to better design and compare
Between a rock and a hard place: 
Pitfalls or just a hard problem?
• Hypoglycaemia?
– Risk of neurological damage?
– Fear of hypoglycaemia?
• Lack of ‘buy-in’ by physicians and nursing staff
• Hyperglycaemia?
– Patients evolve rapidly
– High insulin resistance and insulin requirements
– Insulin effect saturation
– Infrequent measurement ? or ? Burden
• Not doing anything …? Too hard?
There are actually very few “true” pitfalls of IIT
The “rock”
The “hard place”
The Many Practicalities of IIT
• No standard protocols ? variability of care
• Protocol transparency is usually minimal – big complex charts 
or mysterious computer programs
• No standard metrics to assess safety & performance
• Clinical burden?
– Limited nursing resource?
– Education, training 
– ICU layout?
• Compliance is thus an issue and can have the greater effect 
than a (good) protocol
• Who benefits? Which patients and which units?
How to satisfy or meet all these issues and still succeed?
Hypoglycaemia ? ~0-32% Solution
Schultz MJ, Royakkers AANM, Levi M, Moeniralam HS, Spronk PE (2006) Intensive insulin therapy 
in intensive care: An example of the struggle to implement evidence-based medicine. PLoS Med 
3(12): e456. doi:10.1371/journal.pmed.0030456
NB: VISEP sunk with 12% - van den Berghe et al 4-25%
Hypoglycaemia?
Nasraway SA Jr. Hyperglycemia during critical illness. JPEN J Parenter Enteral Nutr. 2006 May-
Jun;30(3):254-8. 
Compliance “… proved to be most difficult…”
Clayton SB, Mazur JE, Condren S, Hermayer KL, Strange C. Evaluation of an intensive insulin 
protocol for septic patients in a medical intensive care unit. Crit Care Med.2006 Dec;34(12):2974-8. 
Transparency
Burden
Compliance
Our Approach – Balance
• Nutritional Inputs
• Endogenous Glucose 
Production
• Exogenous Insulin
• Endogenous Insulin
• Non-insulin Removal
Rising 
Glucose
Falling 
Glucose
• Measure as little as possible (1-2 hours for very critically ill cohort)
• Simple, transparent protocols/methods
• Do simple things, consistently and well, and in moderation
Basic Development
Simulated 
patient trials 
using an 
cortically ill 
cohort
Insulin-nutrition 
model
Simple model with 
saturable dynamics
Clinical Practice 
Improvement
? Implemented 
Aug 2005
Single 
patient 
trials
Clinical Audit 
394 patients
? July 2007
Develop simple 
BALANCED insulin 
& nutrition protocol
? “SPRINT”
Basic Development
Time (minutes)
Dextrose feed and Insulin input
Tight control target = 4-6 mmol/l
Glucose level mmol/l
Feed rate Insulin boluses
Virtual Trials
Short Proof of Concept
Computerised Trials
Implemented as SPRINT
Semi-Automated Feedback Control
Standard infuser equipment
Identify and utilise 
patient specific 
parameters to 
optimise therapy
Patient management
Nursing Staff
Measured data Decision Support System
Minimal time & training – Minimal interruption – Easy to understand 
? Transparent
Control IV Insulin 
and Nutrition
The Cohorts: Before/After Study
• Retrospective before-after study – 1.2 yr SPRINT vs 2.5 yr past
• ROD is higher for SPRINT
– Different case mix with retrospective cohort having much more 
cardiovascular surgery than recently (non-clinical causes)
• Otherwise statistically similar
– Retrospective more cardiovascular surgery so ROD likely lower again
– More similar for LoS > 2 days
 Overall 
 Retrospective SPRINT  
Total patients 516 394  
   p-value 
Age (years) 65  [53 - 74] 65 [50 – 74] 0.22 
% Male 60.1% 62.9% 0.38 
APACHE II score 19 [15 - 24] 18 [14 – 24] 0.06 
APACHE II risk of 
death 
24.1% [11.2% - 45.3%] 25.7% [13.3% - 48.1%] 0.19 
Admission: 2 BG > 144 mg/dL or 1 BG > 180 mg/dL
No exclusions
Cumulative Distribution of BG
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SPRINT
Pre SPRINT
60%
 in 72-110 band
GlucoCard™ measurements 
(Arkray Inc) from venous 
cannula – whole blood 
measurements
28%
72
120
140110
Were Virtual Trials Effective?
• SPRINT was Monte Carlo 
simulated first in to 
show efficacy
• Clinical & virtual results 
are almost identical
• Other protocols were 
simulated and shown for 
comparison
Virtual trials in a Monte Carlo format (for robustness to sensor and other 
errors) are useful to validate models and optimise protocols
Measurements grouped by APACHE II score
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Pre- SPRINT
SPRINT 
Grouped by starting BG
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Blood glucose at initiation of treatment [mg/dL]
Percentage time in 4-6.1 mmol/L band grouped by 
APACHE II score and starting BG
Typical entry levels
DKA and “special” short stay patients
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Nutrition and Insulin Concerns
Matches recent results where tight control via IIT decreased insulin required 
over days 2-7 and thus allows increased nutrition (Langouche et al, 2007)
Avg feed rate exceeded 
@ 2.8 days
Mean Insulin of 2.9 
U/hr most of time in 
days 1-5
• 1279 kcal/day ? 110g/day CHO
• In optimal middle tertile for ROD 
from Krishnan et al, 2005 study
• Nutrition is only useful if it is utilised
SPRINT stopped at 2U/hr 
and ~1300+ kcal/day
Focuses on increasing 
feed as possible using 
“moderate” insulin
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Lowest Recorded BG = 1.6 mmol/L
Not so real
Likely real
Lowest of 28k measurements
Of hypos and “funny” sensors …
• Approximately 1.5-2% of all measurements may be “funny”
– Sudden changes over 36 - 54 mg/dL/hour followed by reverse an hour later after 
a control input change by SPRINT
• 24 total hypo’s ≤ 40 mg/dL (Glucocard, Arkray Inc) and 14 (58%) have 
relatively very high rates of change
• Number where the average rate of change (down and up) was:
– > 36 mg/dL/hour = 14 (~48+% change per 1 hour)
– > 54 mg/dL/hour = 8  (~58+% change per 1 hour)
– > 72 mg/dL/hour = 2 (~65+% change per 1 hour)
• Leaving 10 likely very real hypo’s (0.036% of measures) on 8 patients (2%)
• Compare to 128 (0.44%) in ~30k measurements in Mackenzie et al (2006) 
and reported rates that are higher.
Mackenzie I, Ingle S, Zaidi S, Buczaski S, Hypoglycaemia? So what! Intensive Care Med 
2006;32:620–621 DOI 10.1007/s00134-006-0100-2
Overall SPRINT Glycaemic Control
Overall cohort data Retrospective SPRINT  
   Number of patients 516 394  
   Hours of control 62,769 47,290 hours 
   Total BG measurements 15,618 29,983  
   BG mean (lognormal) 131 108 mg/dL 
   BG standard deviation (lognormal) 43 27 mg/dL 
   Percentage of measurements between:    
      72 – 110 mg/dL 31.5% 59.2%  
      72 – 126 mg/dL 50.3% 79.1%  
      72 – 140 mg/dL 62.9% 86.5%  
   Percentage of measurements less than:    
      72 mg/dL 3.6% 3.9%  
      40 mg/dL 0.2% 0.1%  
   Mean insulin usage 1.0 2.9 U/hr 
   Mean nutrition rate    
      During periods of feeding 1611 1279 kcal/day 
      Entire duration of SPRINT usage - 1055 kcal/day 
   Mean % of goal feed - 66%  
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Blood glucose cumulative distribution for all patients (with at least 20 measurements)
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NOTE: only included patients
with at least 20 measurements
Per-Patient cumulative BG distribution: median, IQR & 90% CI
? Each individual patient’s BG cumulative distribution underneath
The First 48 Hours – All Patients
Red line = median
Box = IQR
Whisker = 1.5*IQR
Red crosses = outliers
Red line = median
Box = IQR
Whisker = 1.5*IQR
Red crosses = outliers
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SPRINT Glycaemic Control Per Patient
• Tighter per patient std deviation – indicates each patient is tighter than the 
cohort to their patient specific mean
• Variability (std deviation) is 20% lower/tighter than retrospective
• Nutrition is actually higher (due to tighter control and less shutoff?)
• Feed shutoff for other clinical reasons can skew results
• Effectively all patients are brought under 7 mmol/L and 96% under 6.1 mmol/L
 Retrospective SPRINT  
Per-patient data    
   Hours of control 57 [25 – 162] 53 [19 – 147] hours 
   Number of BG measurements 17 [8 – 40] 37 [16 – 97]  
   BG mean (lognormal) 135 [121 – 151] 108 [99 – 119] mg/dL 
   BG standard deviation (lognormal) 29 [22 – 43] 23 [18 – 32] mg/dL 
   Percentage of patients < 126 mmol/L 82% 99%  
   Percentage of patients < 110 mmol/L 73% 96%  
   Insulin usage 0.9 [0.1 – 1.6] 2.6 [2.1 – 3.3] U/hr 
   Nutrition rate    
      During periods of feeding 724 [0 – 1596] 938 [0 – 1304] kcal/day 
      Entire duration of SPRINT usage - 708 [0 – 1174] kcal/day 
   % of goal feed - 50% [0% - 71%]  
 
P=0.150 P=0.059 P=0.058 P=0.036
ICU Mortality: SPRINT/Pre-SPRINT
P=0.265
LOS ≥ 2 days LOS ≥ 3 days LOS ≥ 4 days LOS ≥ 5 daysLOS ≥ 1 day
The horizontal line shows the mortality for the retro cohort. The green line
is the total mortality of SPRINT patients against total number of patients 
treated on the protocol
NB: You likely survive or not in LOS < 2 days on merits of initial condition!
# Patients # Patients # Patients # Patients # Patients
P=0.077 P=0.023 P=0.012 P=0.010P=0.244
LOS ≥ 2 days LOS ≥ 3 days LOS ≥ 4 days LOS ≥ 5 daysLOS ≥ 1 day
# Patients # Patients # Patients # Patients # Patients
Hospital Mortality: SPRINT/Pre-SPRINT
The horizontal line shows the mortality for the retro cohort. The green line
is the total mortality of SPRINT patients against total number of patients 
treated on the protocol
NB: You likely survive or not in LOS < 2 days on merits of initial condition!
Nursing Feedback at 2 Months
Survey completed by 26 Christchurch Hospital ICU Nurses
Bottom line: Intuitive and easy for staff to use.
ICU staff workload reduced 
Compliance over 97% (dose)
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Burden Overall Transparency
In Summary: There are no pitfalls…
• It’s just a problem with our expectations and the 
practicalities:
– Desired performance of IIT vs practicalities of implementation
– Nutritional requirements in critical illness and cohort
– Full reporting: per patient and cohort to allow better assessment 
of performance
• It’s a question of balance
– Of therapy choices, practicalities, workload, patient types
– Matching utilisation to supply (in all these things!)
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